Steven L. Highfill

5.3k total citations · 1 hit paper
86 papers, 2.9k citations indexed

About

Steven L. Highfill is a scholar working on Oncology, Immunology and Molecular Biology. According to data from OpenAlex, Steven L. Highfill has authored 86 papers receiving a total of 2.9k indexed citations (citations by other indexed papers that have themselves been cited), including 71 papers in Oncology, 42 papers in Immunology and 32 papers in Molecular Biology. Recurrent topics in Steven L. Highfill's work include CAR-T cell therapy research (62 papers), Immune Cell Function and Interaction (20 papers) and Viral Infectious Diseases and Gene Expression in Insects (18 papers). Steven L. Highfill is often cited by papers focused on CAR-T cell therapy research (62 papers), Immune Cell Function and Interaction (20 papers) and Viral Infectious Diseases and Gene Expression in Insects (18 papers). Steven L. Highfill collaborates with scholars based in United States, France and India. Steven L. Highfill's co-authors include Crystal L. Mackall, Yongzhi Cui, Jillian Smith, Rosandra N. Kaplan, Elizabeth M. Morse, Amber Giles, Bruce R. Blazar, Hua Zhang, Jakub Tolar and David H. Munn and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

In The Last Decade

Steven L. Highfill

81 papers receiving 2.8k citations

Hit Papers

align trajectories sort by overperformance

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Disruption of CXCR2-Mediated MDSC Tumor Trafficking Enhances Anti-PD1 Efficacy

2014 595 citations Steven L. Highfill, Yongzhi Cui et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Steven L. Highfill United States	23	1.7k	1.6k	719	374	348	86	2.9k
Aurore Saudemont United Kingdom	25	2.0k 1.2×	1.8k 1.1×	695 1.0×	654 1.7×	260 0.7×	55	3.0k
Kipp Weiskopf United States	21	2.9k 1.7×	1.2k 0.8×	1.1k 1.6×	178 0.5×	209 0.6×	41	4.1k
Keichiro Mihara Japan	21	645 0.4×	1.2k 0.7×	914 1.3×	491 1.3×	340 1.0×	70	2.4k
Fabio Morandi Italy	35	1.9k 1.1×	1.1k 0.7×	733 1.0×	363 1.0×	156 0.4×	94	3.3k
Adela R. Cardones United States	18	1.2k 0.7×	1.3k 0.8×	486 0.7×	152 0.4×	188 0.5×	61	2.3k
Karen Clise-Dwyer United States	23	1.1k 0.6×	781 0.5×	795 1.1×	248 0.7×	329 0.9×	54	2.2k
Lynne Collins United States	16	1.4k 0.8×	1.1k 0.7×	741 1.0×	391 1.0×	112 0.3×	21	2.4k
Bianca Santomasso United States	19	764 0.4×	3.2k 1.9×	779 1.1×	269 0.7×	683 2.0×	46	3.7k
Ping‐Ying Pan United States	22	3.1k 1.8×	1.6k 1.0×	698 1.0×	143 0.4×	197 0.6×	39	3.8k
Irma Airoldi Italy	33	1.8k 1.1×	1.4k 0.8×	786 1.1×	410 1.1×	204 0.6×	84	2.9k

Countries citing papers authored by Steven L. Highfill

Since Specialization

Citations

This map shows the geographic impact of Steven L. Highfill's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Steven L. Highfill with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Steven L. Highfill more than expected).

Fields of papers citing papers by Steven L. Highfill

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Steven L. Highfill. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Steven L. Highfill. The network helps show where Steven L. Highfill may publish in the future.

Co-authorship network of co-authors of Steven L. Highfill

This figure shows the co-authorship network connecting the top 25 collaborators of Steven L. Highfill. A scholar is included among the top collaborators of Steven L. Highfill based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Steven L. Highfill. Steven L. Highfill is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Dreyzin, Alexandra, Bonnie Yates, Haneen Shalabi, et al.. (2025). Ten-year experience of CD22 CAR T cells for children and young adults with B-cell acute lymphoblastic leukemia. Blood Advances. 10(5). 1700–1712.

Dreyzin, Alexandra, Lipei Shao, Yihua Cai, et al.. (2025). Immunophenotype of CAR T cells and apheresis products predicts response in CD22 CAR T cell trial for B cell acute lymphoblastic leukemia. Molecular Therapy. 33(7). 3360–3374. 3 indexed citations

Henning, Amanda N., et al.. (2025). Assessing the impact of cell isolation method on B cell gene expression using next-generation sequencing. Experimental Hematology. 146. 104766–104766.

Procházková, Michaela, Yihua Cai, Rongye Shi, et al.. (2024). Efficient manufacturing of CAR-T cells from whole blood: a scalable approach to reduce costs and enhance accessibility in cancer therapy. Cytotherapy. 27(3). 400–409. 3 indexed citations

Underwood, Sarah, Jianjian Jin, Lipei Shao, et al.. (2024). T Cell Activators Exhibit Distinct Downstream Effects on Chimeric Antigen Receptor T Cell Phenotype and Function. ImmunoHorizons. 8(6). 404–414. 1 indexed citations

Cai, Yihua, Michaela Procházková, Yongsoo Kim, et al.. (2023). Assessment and comparison of viability assays for cellular products. Cytotherapy. 26(2). 201–209. 10 indexed citations

Kaczanowska, Sabina, Donna Bernstein, Nan Zhang, et al.. (2023). 621 A phase I study of autologous activated NK cells ± rhIL15 in children and young adults with refractory solid tumors. SHILAP Revista de lepidopterología. A708–A708. 1 indexed citations

Ma, Jinxia, Lipei Shao, Hui Liu, et al.. (2023). Reference gene selection for clinical chimeric antigen receptor T-cell product vector copy number assays. Cytotherapy. 25(6). 598–604. 8 indexed citations

Brudno, Jennifer N., Nisha Patel, Roberto Maass‐Moreno, et al.. (2023). Transient responses and significant toxicities of anti-CD30 CAR T cells for CD30+ lymphomas: results of a phase 1 trial. Blood Advances. 8(3). 802–814. 12 indexed citations

10.

Song, Hannah, Alka Dwivedi, Sarah Underwood, et al.. (2023). Manufacture of CD22 CAR T cells following positive versus negative selection results in distinct cytokine secretion profiles and γδ T cell output. Molecular Therapy — Methods & Clinical Development. 32(1). 101171–101171. 7 indexed citations

11.

Smith, Richard H., Danielle Fink, Keyvan Keyvanfar, et al.. (2022). Preclinical Evaluation of Foamy Virus Vector-Mediated Gene Addition in Human Hematopoietic Stem/Progenitor Cells for Correction of Leukocyte Adhesion Deficiency Type 1. Human Gene Therapy. 33(23-24). 1293–1304. 2 indexed citations

12.

Molina, John C., Ting Zhou, Constance M. Yuan, et al.. (2022). Efficacy of second CAR-T (CART2) infusion limited by poor CART expansion and antigen modulation. Journal for ImmunoTherapy of Cancer. 10(5). e004483–e004483. 31 indexed citations

13.

Dreyzin, Alexandra, Sandhya R. Panch, Haneen Shalabi, et al.. (2022). Cryopreserved anti-CD22 and bispecific anti-CD19/22 CAR T cells are as effective as freshly infused cells. Molecular Therapy — Methods & Clinical Development. 28. 51–61. 9 indexed citations

14.

Ramakrishna, Sneha, Steven L. Highfill, Sang M. Nguyen, et al.. (2019). Modulation of Target Antigen Density Improves CAR T-cell Functionality and Persistence. Clinical Cancer Research. 25(17). 5329–5341. 115 indexed citations

15.

Jin, Ping, Wenjing Chen, Jiaqiang Ren, et al.. (2018). Plasma from some cancer patients inhibits adenoviral Ad5f35 vector transduction of dendritic cells. Cytotherapy. 20(5). 728–739. 1 indexed citations

16.

Giles, Amber, Caitlin Marie Reid, Meera Murgai, et al.. (2016). Activation of Hematopoietic Stem/Progenitor Cells Promotes Immunosuppression Within the Pre–metastatic Niche. Cancer Research. 76(6). 1335–1347. 117 indexed citations

17.

Long, Adrienne H., Steven L. Highfill, Yongzhi Cui, et al.. (2016). Reduction of MDSCs with All-trans Retinoic Acid Improves CAR Therapy Efficacy for Sarcomas. Cancer Immunology Research. 4(10). 869–880. 258 indexed citations

18.

Zhou, Qing, David G. Coffey, Steven L. Highfill, et al.. (2014). Nfatc2 and Tob1 Have Non-Overlapping Function in T Cell Negative Regulation and Tumorigenesis. PLoS ONE. 9(6). e100629–e100629. 10 indexed citations

19.

Zhou, Qing, Meghan E. Munger, Steven L. Highfill, et al.. (2010). Program death-1 signaling and regulatory T cells collaborate to resist the function of adoptively transferred cytotoxic T lymphocytes in advanced acute myeloid leukemia. Blood. 116(14). 2484–2493. 230 indexed citations

20.

Ghansah, Tomar, Kim H.T. Paraiso, Steven L. Highfill, et al.. (2004). Expansion of Myeloid Suppressor Cells in SHIP-Deficient Mice Represses Allogeneic T Cell Responses. The Journal of Immunology. 173(12). 7324–7330. 87 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact